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Dare necessary to further evaluate the performance of the de-
cellularized cryopreserved allograft valves in the pulmo-
nary position.References
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Dr James Jaggers (Aurora, Colo). Dr Fortuna and his col-
leagues have presented today a single-institution series of 100 pa-
tients over 7 years that underwent RVOT reconstruction with 39 of
them receiving an SG and 61 receiving an SCA. Importantly,
Dr Fortuna, you have shown that SG valves had superior perfor-
mance with statistically better freedom from conduit failure, con-
duit dysfunction, and conduit replacement at 10 years. This should
be noted to be in contrast with previous experience that showed
a very limited improvement in outcomes with the SG, most of
those related to mild improvement and regurgitation. As you
noted, important limitations of your study and others like this
one regarding its nonrandomized nature, its retrospective nature,
and important differences in the 2 groups leave the audience to
wonder whether these patient groups are really the same. For ex-
ample, there are quite a few more infants receiving smaller allo-
grafts in the SCA group versus the SG group.
I just have 3 brief questions for you. First of all, when you men-
tioned that the echocardiographic analysis was done by a single in-
terpreter, was this interpretation done in a prospective manner or
were these based on previous descriptions in their echocardio-
graphic reports?
Dr Fortuna. Thank you. We obtained the original echocardio-
graphic studies and presented them to a single reviewer in a blinded
fashion. This person reviewed and graded them in a standardized
fashion.
Dr Jaggers. Importantly, did you find any difference when you
analyzed your data between patients who received the orthotopic
versus the heterotopic implant? For example, it is generally recog-
nized that Ross procedure patients have better performance of their
allografts than non-Ross patients. Did you have a chance to look at
your data that way?
Dr Fortuna. I think that is a very good question. It has been
shown at multiple institutions that allografts are more durable
when placed in an orthotopic position versus a heterotopic posi-
tion. In our group we were not able to show any difference.
Dr Jaggers. If you could speculate on the modes of failure, did
you find that the SGs have less calcification? Is there anything that
you can determine that would explain why SGs have improved
performance?
Dr Fortuna. In this retrospective study we did not collect the
tissue samples or systematically study them, but our general im-
pression is that there may be less calcification in the SGs as op-
posed to the SCAs. It is interesting that the function of the valve
seems to be most dramatically affected, and in that case the calci-
fication may play a significant role in the function of those leaflets.
Dr Jaggers. Finally, because these valves are of limited avail-
ability, in your clinical experience, is there a particular patient
group in which you would elect to use an SG versus an SCA?
Dr Fortuna. In our institution our bias is to use the SG in all
patients if we have that opportunity. I think it is a very valid point
that since other studies have shown some risk factors for conduit
failure such as you mentioned, the heterotopic position of the con-
duit, maybe those patients may benefit most from the SG technol-
ogy. We are currently in the process of combining our institution’s
data with those of several other institutions, and our hopes are that
by combining all of that information we will be able to do a more
robust statistical analysis and perhaps do some subgroup analysisery c March 2012
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Das well to provide more information about who would benefit
most.
Dr Jaggers. I enjoyed your paper very much and I think it is go-
ing to be a valuable contribution.
Dr Fortuna. Thank you.
Speaker. I have a question. You are implying that you have 10-
year data, but if I looked at your slides right, at 10 years you had 1
SG patient and 5 SAG patients. Is that correct?
Dr Fortuna. Yes.
Speaker. Do you really consider that to be valid 10-year data.
Dr Fortuna. No, I am not sure that is an entirely valid compar-
ison out at 10 years because of the small numbers, but it does reach
statistical significance. Also, I think you get the sense from looking
at those Kaplan-Meier graphs that there is a divergence in out-
comes between the SGs and the SCAs. Only with longer follow
up will we know whether that maintains statistical significance.The Journal of Thoracic and CaSpeaker. I agree with the early part of your discussion.
Did you make any effort to propensity match these groups, and
don’t you think that would make your data much more believable?
Dr Fortuna. That is a very valid point. We may have been able
to do that. However, we thought there was some value in keeping
a contemporary group for comparison because of other unknown
factors that may affect outcomes. If we did propensity matching
with patients who are taken out of other time periods, for example,
it might be difficult, albeit possible, to take some of those other
factors into consideration. We thought it was best in a single-insti-
tution experiencewith a limited number of patients to take the con-
temporary group in hopes that we are eliminating some of those
other factors.
Speaker. I suggest it may be possible to propensity match even
within your own group, but congratulations on the study.
Dr Fortuna. Thank you.rdiovascular Surgery c Volume 143, Number 3 549
